Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase 1 7Phase 1/2 4Phase 3 2

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 45Genitourinary 14Thoracic 4Other hematologic neoplasm 3Tumor-Agnostic 2Sarcoma 2Dermatologic 2Head & Neck 1Breast 1

Conditions

Sarcoma, Myeloid 1Leukemia, Myeloid, Acute 1Desmoid Tumors 1

Interventions

Doxorubicin 40Radiotherapy 30Ifosfamide 28Vincristine 27Cyclophosphamide 24Imatinib Mesylate 20Etoposide 20Dactinomycin 14Radiation 13Filgrastim 11Temozolomide 9Sunitinib 9Trabectedin 8Methotrexate 8Specimen Handling 7Magnetic Resonance Spectroscopy 6Granulocyte Colony-Stimulating Factor 6Chemotherapy, Adjuvant 6pazopanib 5nilotinib 5Zoledronic Acid 5Neoadjuvant Therapy 5Irinotecan 5Cisplatin 5Carboplatin 5X-Rays 4Vinorelbine 4Topotecan 4Surgical Procedures, Operative 4Procarbazine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Sorafenib × Sarcoma × Clear all
NCT01371981 2026-06-02

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 3 Completed
1,645 enrolled 32 charts
Other hematologic neoplasmSarcoma

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT02066181 2023-06-07

Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis

National Cancer Institute (NCI)

Phase 3 Completed
87 enrolled 14 charts
Sarcoma

Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡